187 related articles for article (PubMed ID: 37097605)
1. Negative Impact of ST-Segment Elevation Myocardial Infarction and Morphine Dose on Ticagrelor Uptake and Pharmacodynamics: A Population PK/PD Analysis of Pooled Individual Participant Data.
Konecki C; Holm M; Djerada Z
Clin Pharmacokinet; 2023 Jun; 62(6):905-920. PubMed ID: 37097605
[TBL] [Abstract][Full Text] [Related]
2. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
[TBL] [Abstract][Full Text] [Related]
3. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration.
Wang Y; Wu H; Chen Y; Wang Q; Qian J; Ge J
Adv Ther; 2020 Oct; 37(10):4220-4232. PubMed ID: 32770531
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
7. The MOVEMENT Trial.
Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
[TBL] [Abstract][Full Text] [Related]
8. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
[TBL] [Abstract][Full Text] [Related]
9. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
Trials; 2015 Apr; 16():198. PubMed ID: 25925591
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial.
Garin D; Degrauwe S; Carbone F; Musayeb Y; Lauriers N; Valgimigli M; Iglesias JF
Front Cardiovasc Med; 2024; 11():1324641. PubMed ID: 38628315
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.
Amilon C; Niazi M; Berggren A; Åstrand M; Hamrén B
Clin Pharmacokinet; 2019 Oct; 58(10):1295-1307. PubMed ID: 30972696
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
[TBL] [Abstract][Full Text] [Related]
13. Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta-analysis.
Batchelor R; Liu DH; Bloom J; Noaman S; Chan W
Catheter Cardiovasc Interv; 2020 Jul; 96(1):76-88. PubMed ID: 31654491
[TBL] [Abstract][Full Text] [Related]
14. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
Franchi F; Rollini F; Park Y; Hu J; Kureti M; Rivas Rios J; Faz G; Yaranov D; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2019 Aug; 12(16):1538-1549. PubMed ID: 31377269
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
Vivas D; Jiménez JJ; Martín-Asenjo R; Bernardo E; Ortega-Pozzi MA; Gómez-Polo JC; Moreno G; Vilacosta I; Pérez-Villacastín J; Fernández-Ortiz A
J Thromb Thrombolysis; 2023 Feb; 55(2):203-210. PubMed ID: 36480147
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
[TBL] [Abstract][Full Text] [Related]
18. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
Adamski P; Ostrowska M; Sikora J; Obońska K; Buszko K; Krintus M; Sypniewska G; Marszałł MP; Koziński M; Kubica J
BMJ Open; 2017 Apr; 7(4):e013218. PubMed ID: 28446521
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment.
Zhang X; Zhang X; Tong F; Cai Y; Zhang Y; Song H; Tian X; Yan C; Han Y
Elife; 2022 Mar; 11():. PubMed ID: 35258452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
